OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD

← catalyst calendar

NCT07450820

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase

—

Status

Completed

Study type

Observational

Enrollment

12,894actual

Sites

Country

Spain

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-02-18

actual

When the study began enrolling

Primary completion

2026-05-06

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-05-06

actual

The whole study's end, after follow-up

First posted

2026-03-05

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-27

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Chronic Kidney Disease